Published in Vaccine on July 05, 2007
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells (2008) 1.38
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer (2011) 1.19
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells. Biomaterials (2008) 1.19
Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother (2010) 1.10
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics (2008) 1.03
Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother (2013) 0.93
Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol (2008) 0.90
Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine (2010) 0.89
Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model. Toxins (Basel) (2012) 0.82
Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice. Arch Immunol Ther Exp (Warsz) (2015) 0.82
Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatol (2012) 0.81
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. Front Immunol (2012) 0.80
Impact of minimal tumor burden on antibody response to vaccination. Cancer Immunol Immunother (2011) 0.79
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. Cancers (Basel) (2011) 0.77
Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clin Exp Metastasis (2014) 0.75
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine (2015) 0.75
Tools to define the melanoma-associated immunopeptidome. Immunology (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.65
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55
Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg (2013) 1.52
Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50
Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol (2004) 1.44
Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J (2002) 1.43
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol (2002) 1.42
Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques. Arch Surg (2012) 1.41
Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.39
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol (2004) 1.32
Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg (2007) 1.32
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg (2006) 1.31
Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification. J Am Coll Surg (2013) 1.29
Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol (2011) 1.29
Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg (2006) 1.28
Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol (2009) 1.25
Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res (2003) 1.24
Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer (2005) 1.23
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23
Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol (2009) 1.22
The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med (2003) 1.21
Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol (2004) 1.20
Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol (2007) 1.19
Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol (2009) 1.18
Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol (2003) 1.18
Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg (2013) 1.18
Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res (2006) 1.18
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17
Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg (2005) 1.15
Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol (2007) 1.14
Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol (2005) 1.12
Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol (2012) 1.11
Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res (2005) 1.11
Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev (2006) 1.11
Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg (2008) 1.10
AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol (2012) 1.09
Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res (2008) 1.09
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem (2009) 1.07
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol (2013) 1.07
Surgery for distant melanoma metastasis. Cancer J (2012) 1.03
Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer (2005) 1.03
Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol (2011) 1.03
Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol (2012) 1.01
Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res (2004) 1.00
Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol (2010) 1.00
Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res (2007) 0.99
The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg (2007) 0.98
Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol (2011) 0.98
Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother (2012) 0.98
Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother (2007) 0.98
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother (2003) 0.98
Solitary dermal melanoma: beginning or end of the metastatic process? Ann Surg Oncol (2009) 0.97
Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res (2004) 0.96
Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol (2003) 0.95
Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol (2007) 0.95
Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol (2002) 0.94
Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res (2014) 0.93
Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol (2003) 0.93
Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol (2003) 0.92
The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions. J Cutan Pathol (2010) 0.92
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol (2014) 0.91